Adjunctive Use of Abciximab during Cerebrovascular Angioplasty and Stenting

ABSTRACT

The incidence of periprocedural neurological events in patients undergoing carotid angioplasty and stenting varies from 3 to 13%. During the period from April 1996 to February 1, 2000, a total of 47 patients underwent cerebrovascular angioplasty, with stenting in 44 patients. In this group of patients 24 patients had the perioperative administration of abciximab. The abciximab group underwent 24 carotid angioplasties and stenting (CAS) procedures, one vertebral origin, and one intracranial vertebral artery angioplasty and stenting. This population was compared with a non-abciximab group of 23 patients undergoing 24 CAS procedures and two angioplasties alone, without abciximab. This preliminary report has demonstrated the feasibility of the use of abciximab in this small patient sample with encouraging ea rly results [non-abcixmab group: 17.3% (13% resolved in 24 hours, 4.3% > 24 hour stroke rate, and 4.3% mortality vs abciximab group: 4.1% stroke rate, 0% mortality with a 4.1% intracranial hemorrhage not requiring surgical intervention).

KEYWORDS

Abciximab - carotid stenting - neurological risks

REFERENCES

• 1 Connors J J, Seidenwurm D, Wojak J C. et al . Treatment of atherosclerotic disease at the cervical carotid bifurcation: current status and review of the literature.  Am J Neuroradiol . 2000;  21 444-450
• 2 Mericle R A, Kim S H, Lanzino G. et al . Carotid artery angioplasty and use of stents in high-risk patients with contralateral occlusions.  J Neurosurg . 1999;  90 1031-1036
• 3 Yadav J S, Roubin G S, Iyer S. Elective stenting of the extracranial carotid arteries.  Circulation . 1997;  95 376-381
• 4 Teitelbaum G P, Lefkowitz M A, Giannotta S L. Carotid angioplasty and stenting in high-risk patients.  Surg Neurol . 1998;  50 300-312
• 5 Wholey M H, Wholey M, Bergeron P. et al . Current global status of carotid stent placement.  Catheterization and Cardiovascular Diagnosis . 1998;  44 1-6
• 6 Mathur A, Roubin G, Gomez C R. et al . Elective carotid artery stenting in the presence of contralateral occlusion.  Am J Cardiol . 1998;  81 1315-1317
• 7 Al-Mubarak N, Roubin G S, Gomez C R. et al . Carotid artery stenting in patients with high neurologic risks.  Am J Cardiol . 1999;  83 1411-1413
• 8 Al-Mubarak N, Roubuin G S, Liu M W. et al . Early results of percutaneous intervention for severe coexisting carotid and coronary artery disease.  Am J Cardiol . 1999;  84 600-602
• 9 New G, Roubin G S, Iyer S S, Vitek J J. Carotid artery stenting: rationale, indications, and results.  Comp Ther . 1999;  25 438-445
• 10 Morris P, Martin E M, Braden G. Intracranial deployment of coronary stents for symptomatic atherosclerotic disease.  Am J Neuroradiol . 1999;  20 1688-1694
• 11 Quereshi A I, Luft A R, Janardhan V. et al . Identification of patients at risk for periprocedural neurological deficits associated with carotid angioplasty and stenting.  Stroke . 2000;  31 376-382
• 12 Jeong M H, Owen W G, Staab M E. et al . Porcine model of stent thrombosis: platelets are the primary component of acute stent closure.  Cathet Cardiovascular Diagn . 1996;  38 38-43
• 13 Kapadia S R, Bajzer C I, Ziada K M. et al .Initial experience of glycoprotien IIb/IIIa inhibition with abciximab during carotid stenting: a safe adjunctive therapy. Abstracts Angiography and Interventional Cardiology, ACCIS 2000, JAAC 86A Feb 2000
• 14 Horwitz A. Integrins and health.  Scientific American . 1997;  68-75
• 15 The Abciximab in Ischemic Stroke Investigators. Abciximab in ischemic stroke: a randomized, double blind, placebo-controlled, dose-escalation study.  Stroke . 2000;  31 601-609
• 16 Abumiya T, Lucero J, Heo H J. et al . Activated microvessels expressed vascular endothelial growth factor and integrin alphaVbetaIII during focal cerebral ischemia.  J Cerebral Blood Flow and Metabolism . 1999;  19 1038-1050
• 17 DeGraba T J, Siren A L, Penix L. et al . Increased endothelial expression of intercellular adhesion molecule-1 in symptomatic versus asymptomatic human carotid atherosclerotic plaque.  Stroke . 1998;  29 1405-1410
• 18 Ross R. Atherosclerosis: an inflammatory disease.  N Engl J Med . 1999;  340 115-126
• 19 Rosenberg R D, Aird W C. Vascular-bed-specific hemostasis and hypercoagulable states.  N Engl J Med . 1999;  20 1555-1564
• 20 The EPIC Investigators. The use of a monoclonal antibody directed against the platelet glyocoprotein IIb/IIIa receptor in high-risk coronary angioplasty.  N Engl J Med . 1994;  330 956-961
• 21 Kereiakes D J. Oral blockade of the platelet glycoprotien IIb/IIIa receptor: fact or fancy?.  American Heart Journal. 138 S39-S46
• 22 The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularizations.  N Engl J Med . 1997;  336 1689-1696
• 23 The Epistent Investigators. Randomized placebo-controlled and balloon angioplasty controlled trial to assess safety of coronary stenting with the use of platelet glycoprotein IIb/ IIIa blockade.  Lancet. 352 87-92
• 24 Topol E J, Califf R M, Weisman H F. et al . Randomized trial of coronary interventions with an antibody against platelet IIb/ IIIa integrin for reduction of clinical restenosis.  Lancet . 1994;  343 881-886
• 25 Gibson C M, Murphy S A, Rizzo M J. et al . Relationship between TIMI frame count and clinical outcomes after thrombolytic administration.  Circulation . 1999;  1945-1950
• 26 Farb A, Sangiorgi G, Carter A J. et al . Pathology of acute and chronic coronary stenting in humans.  Circulation . 1999;  99 44-52
• 27 Peipgras D G, Morgan M K, Sundt T M. et al . Intracerebral hemorrhage after carotid endarterectomy.  J Neurosurg . 1988;  68 532-536
• 28 Sundt T M, Sandok B A, Whisnant J P. Carotid endarterectomy: complications and preoperative assessment of risk.  Mayo Clinic Proceedings . 1975;  50 301-306
• 29 Mori T, Fukuoka M, Kazita K, Mima T, Mori K. Intraventricular hemorrhage after carotid stenting.  J Endovascular Surgery . 1999;  6 337-341
• 30 Qureshi A I, Saadf M, Zaidat O O. et al . Intracerebral hemorrhages associated with neurointerventional procedures using a combination of antithrombotic agents including abciximab.  Stroke . 2002;  33 1916-1919
• 31 Willfort-Ehringer A, Ahmadi R, Gschwandtner M, Haumer M, Lang W, Minar E. Single-center experience with carotid stent restenosis.  J Endovascular Ther . 2002;  9 299-307
• 32 Hofmann R, Kerschner K, Steinwender C, Kypta A, Dietmar B, Leisch F. Abciximab bolus injection does not reduce cerebral ischemic complication of elective carotid artery stenting: a randomized study.  Stroke . 2002;  33 725-727
• 33 Schneiderman J, Morag B, Gerniak A. et al . Abciximab in carotid stenting for postsurgical carotid restenosis: intermediate results.  J Endovasc Ther . 2000;  7 263-272